Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib as Bridging Therapy for HCC Patients on Liver Transplant Waiting List
NCT05901194Phase 2Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Assistance publique - Hôpitaux de Paris. Started Jul 2024; status: active, not recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05901194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05901194.